Human Neural Stem Cells with GDNF Site-Specific Integration at AAVS1 by Using AAV Vectors Retained Their Stemness

  • Jinju Zhang
  • Xiaomei Liu
  • Yun Zhang
  • Zuo Luan
  • Yinxiang Yang
  • Zhaoyan Wang
  • Chun Zhang
Original Paper
  • 26 Downloads

Abstract

The neural stem cells (NSCs) have the ability to self-renew, and to migrate to pathologically altered regions of the central nervous system. Glial cell derived neurotrophic factor (GDNF) could protect dopamine neurons and rescue motor neurons in vivo, which has been proposed as a promising candidate for the treatments of degenerative neurological diseases. In order to combine the advantages of neurotrophic factors and stem cells in clinical therapy, we established the modified hNSCs that has site-specific integration of GDNF gene by using recombinant adeno-associated virus (rAAV) vectors. The hNSCs were co-infected by rAAV2-EGFP-GDNF and rAAV2-SVAV2 which provide integrase to specifically integrate GDNF gene into AAVS1 site. The GDNF-hNSCs maintained their original stem cell characteristics and the ability to differentiate into neurons in vitro. In the animal model, the GDNF-hNSCs were specifically transplanted into CA1 area of hippocampi and could migrate to the dentate gyrus region and differentiate into neuronal cells while maintaining GDNF expression. hNSCs with GDNF gene site-specific integration at AAVS1 by using AAV vectors retained their stemness and effectively expressed GDNF, which indicates the potential of employing transplanted hNPCs for treatment of brain injuries and degenerative neurological diseases.

Keywords

Human neural stem cells (hNSCs) Glial-derived neurotrophic factor (GDNF) Gene therapy Recombinant adeno-associated virus (rAAV) 

Notes

Acknowledgements

This work was supported by Grants from the National Natural Science Foundation of China (81371670), the Key Technology Support Program of Jiangsu Province (Grant No. BE2014638), and the Science and Technology Program of Suzhou (Grant No. ZXY201432).

Compliance with Ethical Standards

Conflict of interest

The authors state no financial/commercial conflicts of interest.

References

  1. 1.
    Gage FH (2000) Mammalian neural stem cells. Science 287(5457):1433–1438.  https://doi.org/10.1126/science.287.5457.1433 CrossRefPubMedGoogle Scholar
  2. 2.
    Svendsen CN, Caldwell NA, Ostenfeld T (1999) Human neural stem cells: Isolation, expansion and transplantation. Brain Pathol 9(3):499–513CrossRefPubMedGoogle Scholar
  3. 3.
    Hsu YC, Lee DC, Chiu IM (2007) Neural stem cells, neural progenitors, and neurotrophic factors. Cell Transpl 16(2):133–150Google Scholar
  4. 4.
    Lindvall O, Kokaia Z (2005) Stem cell therapy for human brain disorders. Kidney Int 68(5):1937–1939.  https://doi.org/10.1111/j.1523-1755.2005.00623.x CrossRefPubMedGoogle Scholar
  5. 5.
    Melone MA, Jori FP, Peluso G (2005) Huntington’s disease: new frontiers for molecular and cell therapy. Curr Drug Targets 6(1):43–56CrossRefPubMedGoogle Scholar
  6. 6.
    Schultz SS (2005) Adult stem cell application in spinal cord injury. Curr Drug Targets 6(1):63–73CrossRefPubMedGoogle Scholar
  7. 7.
    Imitola J (2007) Prospects for neural stem cell-based therapies for neurological diseases. Neurotherapeutics 4(4):701–714.  https://doi.org/10.1016/j.nurt.2007.08.005 CrossRefPubMedGoogle Scholar
  8. 8.
    Sukhikh GT, Malaitsev VV (2001) Neural stem cell: biology and prospects of neurotransplantation. Bull Exp Biol Med 131(3):203–212CrossRefPubMedGoogle Scholar
  9. 9.
    Airaksinen MS, Saarma M (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3(5):383–394.  https://doi.org/10.1038/nrn812 CrossRefPubMedGoogle Scholar
  10. 10.
    Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Therapeut 138(2):155–175.  https://doi.org/10.1016/j.pharmthera.2013.01.004 CrossRefGoogle Scholar
  11. 11.
    Domanskyi A, Saarma M, Airavaara M (2015) Prospects of neurotrophic factors for Parkinson’s disease: comparison of protein and gene therapy. Hum Gene Ther 26(8):550–559.  https://doi.org/10.1089/hum.2015.065 CrossRefPubMedGoogle Scholar
  12. 12.
    Olanow CW, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, Henderson JM, Stern M, Baltuch G, Goetz CG, Herzog C, Kordower JH, Alterman R, Lozano AM, Lang AE (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 78(2):248–257.  https://doi.org/10.1002/ana.24436 CrossRefGoogle Scholar
  13. 13.
    Walton KM (1999) GDNF: a novel factor with therapeutic potential for neurodegenerative disorders. Mol Neurobiol 19(1):43–59CrossRefPubMedGoogle Scholar
  14. 14.
    Linden RM, Winocour E, Berns KI (1996) The recombination signals for adeno-associated virus site-specific integration. Proc Natl Acad Sci U S A 93(15):7966–7972.  https://doi.org/10.1073/pnas.93.15.7966 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Philpott NJ, Gomos J, Berns KI, Falck-Pedersen E (2002) A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19. Proc Natl Acad Sci USA 99(19):12381–12385.  https://doi.org/10.1073/pnas.182430299 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Balague C, Kalla M, Zhang WW (1997) Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 71(4):3299–3306PubMedPubMedCentralGoogle Scholar
  17. 17.
    Recchia A, Perani L, Sartori D, Olgiati C, Mavilio F (2004) Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol Ther 10(4):660–670.  https://doi.org/10.1016/j.ymthe.2004.07.003 CrossRefPubMedGoogle Scholar
  18. 18.
    Ogata T, Kozuka T, Kanda T (2003) Identification of an insulator in AAVS1, a preferred region for integration of adeno-associated virus DNA. J Virol 77(16):9000–9007.  https://doi.org/10.1128/Jvi.77.16.9000-9007.2003 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Luan Z, Qu S, Du K, Liu W, Yang Y, Wang Z, Cui Y, Du Q (2013) Neural stem/progenitor cell transplantation for cortical visual impairment in neonatal brain injured patients. Cell Transpl 22(Suppl 1):S101–S112.  https://doi.org/10.3727/096368913X672163 CrossRefGoogle Scholar
  20. 20.
    Zhang C, Cortez NG, Berns KI (2007) Characterization of a bipartite recombinant adeno-associated viral vector for site-specific integration. Hum Gene Ther 18(9):787–797.  https://doi.org/10.1089/hum.2007.056 CrossRefPubMedGoogle Scholar
  21. 21.
    Aurnhammer C, Haase M, Muether N, Hausl M, Rauschhuber C, Huber I, Nitschko H, Busch U, Sing A, Ehrhardt A, Baiker A (2012) Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther Methods 23(1):18–28.  https://doi.org/10.1089/hgtb.2011.034 CrossRefPubMedGoogle Scholar
  22. 22.
    Gao J, Prough DS, McAdoo DJ, Grady JJ, Parsley MO, Ma L, Tarensenko YI, Wu P (2006) Transplantation of primed human fetal neural stem cells improves cognitive function in rats after traumatic brain injury. Exp Neurol 201(2):281–292.  https://doi.org/10.1016/j.expneurol.2006.04.039 CrossRefPubMedGoogle Scholar
  23. 23.
    Bartlett JS, Samulski RJ, McCown TJ (1998) Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther 9(8):1181–1186.  https://doi.org/10.1089/hum.1998.9.8-1181 CrossRefPubMedGoogle Scholar
  24. 24.
    Kearns CM, Gash DM (1995) Gdnf protects nigral dopamine neurons against 6-hydroxydopamine in-vivo. Brain Res 672(1–2):104–111.  https://doi.org/10.1016/0006-8993(94)01366-P CrossRefPubMedGoogle Scholar
  25. 25.
    Gash DM, Zhang ZM, Ai Y, Grondin R, Coffey R, Gerhardt GA (2005) Trophic factor distribution predicts functional recovery in Parkinsonian monkeys. Ann Neurol 58(2):224–233.  https://doi.org/10.1002/ana.20549 CrossRefPubMedGoogle Scholar
  26. 26.
    Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59(3):459–466.  https://doi.org/10.1002/ana.20737 CrossRefPubMedGoogle Scholar
  27. 27.
    Lim ST, Airavaara M, Harvey BK (2010) Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 61(1):14–26.  https://doi.org/10.1016/j.phrs.2009.10.002 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Cell and Gene Therapy CenterSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of SciencesSuzhouPeople’s Republic of China
  2. 2.CAS Key Lab of Bio-Medical DiagnosticsSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of SciencesSuzhouPeople’s Republic of China
  3. 3.University of Chinese Academy of SciencesBeijingPeople’s Republic of China
  4. 4.Navy General Hospital of PLA ChinaBeijingPeople’s Republic of China

Personalised recommendations